Guilin Sanjin Pharmaceutical Future Growth
Future criteria checks 5/6
Guilin Sanjin Pharmaceutical is forecast to grow earnings and revenue by 34.1% and 25.3% per annum respectively while EPS is expected to grow by 34.1% per annum.
Key information
34.1%
Earnings growth rate
34.1%
EPS growth rate
Pharmaceuticals earnings growth | 18.6% |
Revenue growth rate | 25.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 31 Oct 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 3,097 | 682 | N/A | 623 | 2 |
12/31/2024 | 2,671 | 580 | N/A | 599 | 2 |
3/31/2024 | 1,938 | 352 | 449 | 520 | N/A |
12/31/2023 | 2,172 | 421 | 473 | 549 | N/A |
9/30/2023 | 2,153 | 402 | 430 | 514 | N/A |
6/30/2023 | 2,158 | 406 | 439 | 509 | N/A |
3/31/2023 | 2,159 | 379 | 361 | 415 | N/A |
12/31/2022 | 1,960 | 330 | 466 | 529 | N/A |
9/30/2022 | 1,925 | 375 | 371 | 364 | N/A |
6/30/2022 | 1,857 | 399 | 307 | 420 | N/A |
3/31/2022 | 1,829 | 366 | 252 | 404 | N/A |
1/1/2022 | 1,741 | 344 | 266 | 410 | N/A |
9/30/2021 | 1,724 | 265 | 150 | 400 | N/A |
6/30/2021 | 1,694 | 283 | 171 | 329 | N/A |
3/31/2021 | 1,667 | 298 | 426 | 606 | N/A |
12/31/2020 | 1,566 | 277 | 393 | 598 | N/A |
9/30/2020 | 1,611 | 367 | 360 | 553 | N/A |
6/30/2020 | 1,602 | 359 | 458 | 698 | N/A |
3/31/2020 | 1,592 | 381 | 222 | 452 | N/A |
12/31/2019 | 1,640 | 392 | 242 | 468 | N/A |
9/30/2019 | 1,600 | 377 | 362 | 558 | N/A |
6/30/2019 | 1,619 | 418 | 396 | 501 | N/A |
3/31/2019 | 1,617 | 418 | 534 | 642 | N/A |
12/31/2018 | 1,585 | 413 | 462 | 552 | N/A |
9/30/2018 | 1,649 | 483 | 504 | 558 | N/A |
6/30/2018 | 1,643 | 482 | 423 | 512 | N/A |
3/31/2018 | 1,626 | 472 | 430 | 493 | N/A |
12/31/2017 | 1,616 | 464 | N/A | 411 | N/A |
9/30/2017 | 1,600 | 426 | N/A | 334 | N/A |
6/30/2017 | 1,582 | 418 | N/A | 440 | N/A |
3/31/2017 | 1,559 | 398 | N/A | 499 | N/A |
12/31/2016 | 1,525 | 394 | N/A | 537 | N/A |
9/30/2016 | 1,495 | 406 | N/A | 553 | N/A |
6/30/2016 | 1,448 | 384 | N/A | 479 | N/A |
3/31/2016 | 1,470 | 397 | N/A | 410 | N/A |
12/31/2015 | 1,391 | 377 | N/A | 403 | N/A |
9/30/2015 | 1,408 | 407 | N/A | 398 | N/A |
6/30/2015 | 1,449 | 423 | N/A | 312 | N/A |
3/31/2015 | 1,398 | 424 | N/A | 291 | N/A |
12/31/2014 | 1,466 | 445 | N/A | 397 | N/A |
9/30/2014 | 1,423 | 434 | N/A | 511 | N/A |
6/30/2014 | 1,458 | 449 | N/A | 315 | N/A |
3/31/2014 | 1,429 | 422 | N/A | 421 | N/A |
12/31/2013 | 1,469 | 422 | N/A | 315 | N/A |
9/30/2013 | 1,399 | 374 | N/A | 206 | N/A |
6/30/2013 | 1,362 | 357 | N/A | 494 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002275's forecast earnings growth (34.1% per year) is above the savings rate (2.9%).
Earnings vs Market: 002275's earnings (34.1% per year) are forecast to grow faster than the CN market (24.4% per year).
High Growth Earnings: 002275's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 002275's revenue (25.3% per year) is forecast to grow faster than the CN market (14.6% per year).
High Growth Revenue: 002275's revenue (25.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 002275's Return on Equity is forecast to be high in 3 years time